DPEP1
Dipeptidase 1
As of the edition of 20 October 2026, DPEP1 (dipeptidase 1, UniProt P16444) has 6 drugs tested at it and 8 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16444
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Infections; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Cancer; Digestive system; Inherited and neonatal
- Registered trials of its drugs
- 36
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 3 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cilastatin | Marketed | Phase 4 | Ends 2033 |
| Nacubactam | Active | Phase 3 | none listed |
| Biapenem | Went quiet | Phase 1 | none listed |
| FL058 | Went quiet | Phase 1 | none listed |
| ETX0282 | Went quiet | Phase 1 | none listed |
| QPX7831 | Status not established | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Qilu Pharmaceutical | Route A |
| Entasis Therapeutics | Route A |
The other 5 companies at DPEP1
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at DPEP1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.